01—Abstract
Summary
Summary of the 8-K filed February 6, 2024. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. (Nasdaq: EXEL) filed this Item 2.02 Form 8-K on February 6, 2024 to furnish a press release (Exhibit 99.1) reporting financial results for the fourth quarter and fiscal year ended December 29, 2023 (presented as December 31, 2023) and providing a corporate update.
Total revenues were $479.7 milliona for the fourth quarter and $1,830.2 million for fiscal 2023, compared with $423.9 million and $1,611.1 million in the prior-year periods. Net product revenues were $429.3 million for the quarter and $1,628.9 million for the year, driven by higher sales volume and higher average net selling price. GAAP net income was $85.5 million ($0.27 per diluted share) for the quarter and $207.8 million ($0.65 per diluted share) for the year, while non-GAAP diluted EPS was $0.33 for the quarter and $0.90 for the year.
For 2024, the company maintained its prior guidance: total revenues of $1.825 billion to $1.925 billionb, net product revenues of $1.650 billion to $1.750 billion, and research and development expenses of $925 million to $975 million, excluding costs related to the restructuring plan announced in January 2024. Management highlighted planned regulatory strategies for cabozantinib in neuroendocrine tumors and metastatic castration-resistant prostate cancer, and an anticipated ruling in the second bench trial in the MSN Pharmaceuticals litigation in spring 2024. The board authorized up to an additional $450 million in share repurchases before the end of 2024, following completion of $550 million under the prior program.
02—Key points
Key Highlights
- Fiscal 2023 total revenues of $1,830.2 million, up from $1,611.1 million in 2022; fourth-quarter revenues of $479.7 million versus $423.9 million.
- Net product revenues of $1,628.9 million for fiscal 2023 (Q4: $429.3 million), attributed to higher sales volume and higher average net selling price.
- GAAP diluted EPS of $0.65 for fiscal 2023 and $0.27 for Q4; non-GAAP diluted EPS of $0.90 for fiscal 2023 and $0.33 for Q4.
- 2024 guidance maintained: total revenues of $1.825–$1.925 billion and net product revenues of $1.650–$1.750 billion; R&D expenses of $925–$975 million and SG&A of $425–$475 million, excluding restructuring costs.
- New share repurchase authorization of up to an additional $450 million before the end of 2024, after completing $550 million (26.2 million shares) under the prior program.
- Regulatory plans for cabozantinib in advanced NET and mCRPC, supported by CABINET and CONTACT-02 trial data; company expects to discuss a potential NET submission with the FDA in 2024.
- Pipeline and corporate updates include the zanzalintinib STELLAR-305 phase 2/3 trial initiation, the restructuring announced in January 2024, and two new board appointments effective January 5, 2024.
03—Questions
Frequently Asked Questions
How did Exelixis perform financially in fiscal 2023?
Total revenues were $1,830.2 million for fiscal 2023, versus $1,611.1 million in 2022. GAAP net income was $207.8 million ($0.65 per diluted share), compared with $182.3 million ($0.56 per diluted share) a year earlier. Non-GAAP diluted EPS was $0.90.
What is the company's 2024 financial guidance?
Exelixis maintained its prior 2024 guidance: total revenues of $1.825 billion to $1.925 billion, net product revenues of $1.650 billion to $1.750 billion, R&D expenses of $925 million to $975 million, and SG&A expenses of $425 million to $475 million. The guidance excludes expenses related to the restructuring plan announced in January 2024.
What drove the growth in net product revenues?
The filing states that net product revenues increased primarily due to an increase in sales volume and an increase in average net selling price. Fiscal 2023 net product revenues were $1,628.9 million, compared with $1,401.2 million in 2022.
What capital return actions did the company announce?
In January 2024, the board authorized repurchases of up to an additional $450 million of common stock before the end of 2024. The company completed its prior program, repurchasing 26.2 million shares for a total of $550 million as of December 31, 2023.
What key litigation and regulatory events could affect investors in 2024?
Exelixis anticipates a ruling on the second bench trial in its litigation with MSN Pharmaceuticals this spring (the filing elsewhere says the outcome is anticipated in the first half of 2024). The company also plans to discuss potential regulatory submissions for cabozantinib in advanced neuroendocrine tumors with the FDA in 2024 and will continue discussions on a regulatory path for cabozantinib plus atezolizumab in mCRPC.
04—Continue